What are the top cell therapy startups?

This blog post has been written by the person who has mapped the cell therapy startup market in a clean and beautiful presentation

The cell therapy sector has experienced unprecedented growth with $15.2 billion invested in 2024 alone.

With approximately 3,000 developers and 2,000 clinical trials globally, this rapidly expanding market is projected to reach $47.72 billion by 2034. Companies like ArsenalBio have secured massive funding rounds exceeding $325 million, while pharmaceutical giants continue strategic acquisitions worth billions.

And if you need to understand this market in 30 minutes with the latest information, you can download our quick market pitch.

Which are the most promising cell therapy startups globally right now?

ArsenalBio leads the pack with their programmable CAR-T cell platform specifically designed for solid tumors, having secured $325 million in Series C funding during 2024.

Tmunity Therapeutics has established itself as a frontrunner with $425 million total raised, focusing on T-cell immunotherapies through their integrated platform that combines discovery, development, and manufacturing capabilities. Their approach eliminates traditional bottlenecks by controlling the entire value chain from research to commercial production.

ViaCyte stands out in the diabetes treatment space with $328.8 million raised across 16 funding rounds, developing stem cell-derived pancreatic beta cell precursors. Their clinical programs have shown promising results in type 1 diabetes patients, positioning them as leaders in metabolic disease applications.

Encoded Therapeutics has raised $343.1 million across just 4 funding rounds, demonstrating strong investor confidence in their genomics-driven precision medicine approach. The company combines advanced genetic analysis with targeted cell therapies for rare genetic diseases.

Bit.bio has secured $183.9 million with their revolutionary approach to programming human cells through coding and biology, offering scalable solutions for therapeutic cell manufacturing that could transform production economics.

Which startups have raised the largest funding rounds in 2024 and 2025 so far?

ArsenalBio topped 2024 funding with their massive $325 million Series C round, bringing their total funding to $700 million since inception.

AvenCell Therapeutics secured $112 million in Series B funding in October 2024, led by Novo Holdings, for their Universal Switchable CAR-T cell therapy platform. This technology allows for enhanced control and safety mechanisms in CAR-T treatments, addressing key concerns about cytokine release syndrome.

Capstan Therapeutics raised $175 million in Series B funding in March 2024, focusing on their innovative cell therapy development platform. The company's technology enables more efficient manufacturing processes and improved therapeutic outcomes through enhanced cell engineering capabilities.

Neurona Therapeutics completed a $102 million funding round for their cell therapy treatments targeting neurological disorders. Their approach uses transplanted interneurons to treat epilepsy and other neurological conditions, representing a novel therapeutic modality.

Kyverna Therapeutics achieved a significant milestone with their $319 million IPO in 2024, focusing on anti-CD19 CAR-T therapies for autoimmune diseases. This public offering demonstrated strong market confidence in expanding CAR-T applications beyond oncology into autoimmune disorders.

If you want fresh and clear data on this market, you can download our latest market pitch deck here

Who are the key investors backing these leading cell therapy startups and what amounts have they invested?

Novo Holdings dominates as the most active investor in cell therapy, consistently leading late-stage funding rounds with investments exceeding $500 million across multiple companies.

ARCH Venture Partners has invested over $300 million in cell therapy startups, focusing on companies with breakthrough platform technologies. Their portfolio includes several companies developing next-generation CAR-T therapies and novel cell engineering approaches.

Forbion Ventures has committed approximately $250 million to European cell therapy companies, particularly those developing allogeneic cell therapies that eliminate the need for patient-specific manufacturing. Their geographic focus on Europe has supported the region's growing cell therapy ecosystem.

Frazier Life Sciences has invested heavily in late-stage cell therapy companies, with over $200 million deployed across their portfolio. They typically invest in companies with established clinical data and clear paths to commercialization.

Corporate venture capital arms from Bristol Myers Squibb, Sanofi, Eli Lilly, and Merck have collectively invested over $1 billion in cell therapy startups through 2024-2025, seeking access to next-generation drug pipelines and innovative therapeutic modalities.

Are there any major pharmaceutical or biotech giants partnering with or investing in these startups?

AstraZeneca made the largest acquisition of 2025, purchasing EsoBiotec for $1 billion to advance their cell therapy capabilities through the revolutionary EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform.

Bristol Myers Squibb acquired 2seventy bio for $286 million in March 2025, continuing their strategic focus on CAR-T cell therapies. This acquisition strengthens their position in multiple myeloma treatments and expands their cell therapy manufacturing capabilities.

Sanofi acquired Dren Bio's bispecific myeloid cell engager technology for $600 million upfront, demonstrating their commitment to innovative immunotherapy approaches. This deal includes potential milestone payments that could reach $1.2 billion based on development and commercial achievements.

Prime Medicine established a significant partnership with Bristol Myers Squibb for next-generation ex vivo cell therapies, combining Prime's base editing technology with Bristol Myers Squibb's cell therapy expertise and manufacturing infrastructure.

Need a clear, elegant overview of a market? Browse our structured slide decks for a quick, visual deep dive.

Which startups have received notable awards or industry recognition recently?

OXB won the prestigious 2025 CDMO Leadership Award in the 'Cell & Gene Therapy – Global' category, recognizing their excellence in contract development and manufacturing services that support numerous startups in scaling their therapies.

Beam Therapeutics received FDA orphan drug designation for BEAM-101, their base editing therapy for sickle cell disease. This designation provides significant regulatory advantages including extended market exclusivity and reduced FDA fees.

Sarepta Therapeutics achieved FDA platform technology designation for their viral vector platform, enabling streamlined regulatory pathways for future therapies. This recognition accelerates development timelines and reduces regulatory uncertainty for their pipeline programs.

BlueRock Therapeutics was recognized with the Best Company Culture 2021 award, highlighting their innovative approach to employee engagement and scientific collaboration. Their culture of innovation has contributed to breakthrough developments in iPSC-derived cell therapies.

The International Society for Cell & Gene Therapy (ISCT) continues to present Career Achievement Awards and Trailblazer Awards to recognize outstanding contributions to the field, with several startup founders receiving these honors for their pioneering work in advancing cell therapy technologies.

What geographical regions are the most active hubs for these leading cell therapy startups?

North America dominates with 59% market share in 2024, driven by advanced healthcare infrastructure, substantial R&D investments, and favorable regulatory environments.

The Boston-Cambridge corridor remains the leading global hub with over 150 cell therapy companies, benefiting from proximity to world-class research institutions like MIT and Harvard. The San Francisco Bay Area follows closely with major companies like Allogene Therapeutics and numerous emerging startups.

San Diego has established itself as a major cell therapy cluster with over 80 companies, leveraging its strong biotech ecosystem and experienced talent pool. The region benefits from established infrastructure and successful exits that have created a robust investment environment.

Europe accounts for 37% of total venture capital investment, with the UK leading at 29% of all European ATMP companies. Cambridge, UK, and Basel, Switzerland, serve as major European hubs with strong academic-industry partnerships and supportive regulatory frameworks.

Asia-Pacific represents the fastest-growing region, expected to reach 20% market share by 2026. Singapore has evolved into a major therapeutic product development hub, while China dominates CAR-T clinical trials with 55% of global trials, though regulatory challenges remain for international market access.

If you need to-the-point data on this market, you can download our latest market pitch deck here

What are the most important technological breakthroughs in cell therapy R&D achieved so far in 2025?

EsoBiotec's ENaBL platform represents the most significant breakthrough, enabling cell therapies to be administered through simple IV injection rather than complex ex vivo processing.

Vertex Pharmaceuticals and Neurona Therapeutics achieved landmark results in type 1 diabetes and epilepsy treatment using lab-made stem cells. These breakthrough therapies demonstrated that patients could achieve insulin independence and significant seizure reduction, respectively.

New gene editing platforms offering longer DNA inserts have emerged, promising to expand therapeutic capabilities beyond current CRISPR, base, and prime editing limitations. These platforms enable more complex genetic modifications and therapeutic programming capabilities.

Automated and scalable manufacturing processes have reached commercial viability, making cell therapies more affordable and accessible. Closed-system manufacturing and AI-driven quality control are becoming standard practice to reduce contamination risks and improve production efficiency.

Wondering who's shaping this fast-moving industry? Our slides map out the top players and challengers in seconds.

Which breakthroughs or innovations are expected from these startups in 2026?

CAR-T therapies are expected to show significant progress in solid tumor applications, building on recent FDA approvals from Iovance and Adaptimmune that have validated the approach in challenging cancer types.

Autoimmune applications represent the next major expansion area, with CAR-T therapies showing promise in lupus, rheumatoid arthritis, and type 1 diabetes. Multiple companies are advancing programs that could transform treatment of autoimmune disorders.

Universal donor approaches through allogeneic cell therapies are expected to gain significant traction as manufacturing scalability improves. Companies like Allogene Therapeutics are leading this shift toward off-the-shelf therapies that eliminate patient-specific manufacturing requirements.

In vivo cell therapy delivery systems are projected to reach clinical validation, potentially eliminating the need for complex ex vivo processing. This breakthrough could dramatically reduce costs and improve patient access to cell therapies.

AI-driven cell therapy design and manufacturing optimization are expected to mature, enabling more precise therapeutic programming and improved manufacturing efficiency. These advances could reduce production costs by 50% or more while improving therapeutic efficacy.

Which startup has raised the most capital overall in this sector?

ArsenalBio leads with $700 million total raised across multiple funding rounds, establishing them as the most well-funded cell therapy startup globally.

Tmunity Therapeutics follows closely with $425 million total funding, demonstrating strong investor confidence in their integrated T-cell immunotherapy platform. Their funding progression shows consistent growth with each round substantially larger than the previous.

Encoded Therapeutics has achieved remarkable capital efficiency with $343.1 million raised across only 4 funding rounds, indicating strong investor conviction and rapid value creation milestones.

ViaCyte has secured $328.8 million across 16 funding rounds, representing one of the longest funding histories in the sector. Their sustained fundraising ability demonstrates the long-term potential of their diabetes-focused approach.

Looking for the latest market trends? We break them down in sharp, digestible presentations you can skim or share.

If you want actionable data about this market, you can download our latest market pitch deck here

What is the total amount invested in the cell therapy startup sector globally in 2024 and 2025 so far?

The cell therapy sector received $15.2 billion in total investment during 2024, representing a 30% increase from the previous year and demonstrating strong investor confidence despite broader market challenges.

2025 investment through mid-year has already reached $8.7 billion, putting the sector on track to exceed 2024 totals with continued strong funding momentum. The median biotech venture round has remained near $100 million, continuing the trend toward larger "megarounds."

North American investors have increased their share of funding, particularly in later-stage deals, while European investment has remained stable at approximately 37% of total venture capital investment. Asia-Pacific investment has grown significantly, representing the fastest-growing regional market.

Corporate venture capital participation has intensified, with pharmaceutical companies investing over $3 billion across the sector in 2024-2025. This represents a significant increase from previous years as large pharma seeks access to innovative therapeutic platforms.

The average funding round size has increased to $127 million in 2025, up from $98 million in 2023, indicating both increased capital requirements for clinical development and greater investor willingness to fund larger rounds for promising companies.

What are the expected investment trends and funding outlook for this sector in 2026?

Continued focus on late-stage assets is expected, with investors maintaining their preference for Phase 2+ companies that have clear clinical data and defined paths to commercialization.

The megaround trend is projected to persist, with median rounds expected to remain near $100 million as companies require substantial capital for manufacturing scale-up and clinical development. Investors are consolidating their investments into fewer, larger bets on companies with proven platforms.

Geographic expansion into Asia-Pacific markets is anticipated to accelerate, with the region projected to show 16% CAGR growth driven by favorable regulations, lower clinical trial costs, and increasing local investment capabilities.

Corporate venture capital activity is expected to intensify further, with pharmaceutical companies increasing their investment focus on cell therapy platforms that complement their existing pipelines. Strategic partnerships and acquisitions are likely to increase as companies seek to access innovative technologies.

Planning your next move in this new space? Start with a clean visual breakdown of market size, models, and momentum.

Are there any unique or distinguishing traits that set these top startups apart from others in the space?

Platform-based approaches distinguish the leading companies, with firms like ArsenalBio and Tmunity Therapeutics developing programmable systems that can address multiple therapeutic areas rather than single-indication therapies.

• Allogene Therapeutics stands out with their AlloCAR T™ therapy using healthy donor T cells, eliminating the need for personalized therapy manufacturing for each patient and potentially reducing costs by 70%
• BlueRock Therapeutics offers a unique cell+gene platform that reprograms mature cells back to induced pluripotent stem cells (iPSCs), enabling scalable therapeutic cell production
• TreeFrog Therapeutics developed C-Stem technology for safe and efficient scaling of therapeutic cell manufacturing, addressing critical production bottlenecks
• Aspen Neuroscience focuses specifically on autologous iPSC-derived cell replacement therapies for Parkinson's disease, leveraging patient-specific approaches for enhanced safety
• Cellino Biotech is building the first autonomous cell treatment manufacturing system with AI-driven quality control, potentially revolutionizing production efficiency

Manufacturing innovation serves as a key differentiator, with companies investing heavily in automated, closed-system processes that reduce contamination risks and improve scalability. Modular cleanroom solutions and decentralized manufacturing models are becoming competitive advantages.

Therapeutic area specialization allows companies to develop deep expertise in specific disease applications, with some focusing on oncology, others on autoimmune disorders, and emerging players targeting neurological conditions and metabolic diseases.

Conclusion

Sources

1. Quick Market Pitch - Cell Therapy Market Size
2. MedPath - Cell and Gene Therapy Sector Growth Report
3. Precedence Research - Cell Therapy Market Analysis
4. BioPharma Dive - ArsenalBio Series C Funding
5. SeedTable - Best Cell Therapy Startups
6. AvenCell - Series B Funding Announcement
7. Fierce Biotech - Fundraising Tracker 2025
8. Globe Newswire - CAR-T Funding Report 2025
9. Gilion - Biotech Venture Capital Mapping
10. BioPharma Dive - Q1 2025 Biotech Venture Capital Report
11. AstraZeneca - EsoBiotec Acquisition Announcement
12. LabioTech - Top Biotech Deals March 2025